A hemagglutinin-derived peptide-vaccine ignored by virus-neutralizing passive antibodies, protects against murine measles encephalitis

Vaccine

Volumn 17, Issue 19, 1999, Pages 2436-2445

  El Kasmi, Karim C ^a,b   Theisen, Dietmar ^a   Brons, Nicolaas H C ^a   Ammerlaan, Wim ^a   Klingele, Matthias ^a,b   Truong, Anh T ^a   Muller, Claude P ^a,b  

^a LABORATOIRE NATIONAL DE SANTÉ   (Luxembourg)

^b UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

Author keywords

Linear epitope; Measles virus; Neutralization

Indexed keywords

CROSS REACTING ANTIBODY; EPITOPE; HEMAGGLUTININ; LIVE VACCINE; MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY;

ANIMAL MODEL; ARTICLE; ENCEPHALITIS; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IMMUNE RESPONSE; IMMUNIZATION; MEASLES VIRUS; NONHUMAN; PRIORITY JOURNAL; PROTEIN CONFORMATION; SEROCONVERSION; VIRUS REPLICATION; VIRUS STRAIN;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODY SPECIFICITY; ENCEPHALITIS, VIRAL; EPITOPES, B-LYMPHOCYTE; EPITOPES, T-LYMPHOCYTE; FEMALE; HEMAGGLUTININS, VIRAL; IMMUNE SERA; IMMUNIZATION, PASSIVE; INJECTIONS, INTRAPERITONEAL; MALE; MEASLES; MEASLES VIRUS; MICE; MICE, INBRED BALB C; NEUTRALIZATION TESTS; PEPTIDES; SURVIVAL RATE; VIRAL VACCINES;

EID: 0033553612     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(99)00008-0     Document Type: Article

References (48)

1. World health report, 1996. Fighting disease, fostering development. WHO, Geneva, Switzerland.
2. Sabin A.B. My last will and testament on rapid elimination and ultimate global eradication of poliomyelitis and measles. Pediatrics. 90:1992;162-169.
3. Sato H., Albrecht P., Reynolds D.W., Stagno S., Ennis F.A. Transfer of measles, mumps, and rubella antibodies from mother to infant. Its effect on measles, mumps, and rubella immunisation. Am. J. Dis. Child. 133:1979;1240-1243.
4. Siber G.R., Werner B.G., Halsey N.A., Reid R., Almeido-Hill J., Garrett S.C., Thompson C., Santosham M. Interference of immune globulin with measles and rubella immunisation. J. Pediatr. 122:1993;204-211.
5. Gans H., Arvin A.M., Galinus J., Logan L., DeHovitz Y. Deficiency of the humoral immune response to measles vaccine in infants immunised at six months of age. JAMA 1998, in press.
6. Albrecht P., Ennis F.A., Saltzman E.J., Krugman S. Persistence of maternal antibody in infants beyond 12 months: mechanism of measles vaccine failure. J. Pediatr. 91:1977;715-718.
7. Giraudon P., Wild T.F. Correlation between epitopes on hemagglutinin of measles virus and biological activities: passive protection by monoclonal antibodies is related to their hemagglutination inhibiting activity. Virology. 144:1985;46-58.
8. Norrby E., Hammarskjold B. Structural components of measles virus. Microbios. 5:1972;17-29.
9. Varsanyi T.M., Utter G., Norrby E. Purification, morphology and antigenic characterization of measles virus envelope components. J. Gen. Virol. 65:1984;355-366.
10. Fournier P., Brons N.H., Berbers G., Wiesmuller K.H., Fleckenstein B.T., Schneider F., Jung G., Muller C.P. Antibodies to a new linear site at the topographical or functional interface between the haemagglutinin and fusion proteins protect against measles encephalitis. J. Gen. Virol. 78:1997;1295-1302.
11. Langedijk J.P., Daus F.J., van Oirschot J.T. Sequence and structure alignment of Paramyxoviridae attachment proteins and discovery of enzymatic activity for a morbillivirus hemagglutinin. J. Virol. 71:1997;6155-6167.
12. Bartz R., Brinckmann U., Dunster L.M., Rima B., Ter Meulen V., Schneider-Schaulies J. Mapping amino acids of the measles virus hemagglutinin responsible for receptor (CD46) downregulation. Virology. 224:1996;334-337.
13. Deroo S., El Kasmi K.C., Fournier P., Theisen D., Brons N.H.C., Herrmann M., Desmet J., Muller C.P. Enhanced antigenicity of a four-contact-residue epitope of the measles virus hemagglutinin protein by phage display libraries: evidence of a helical structure in the putative active site. Mol. Immunol. 35:1998;435-443.
14. Obeid O.E., Partidos C.D., Howard C.R., Steward M.W. Protection against morbillivirus-induced encephalitis by immunisation with a rationally designed synthetic peptide vaccine containing B- and T-cell epitopes from the fusion protein of measles virus. J. Virol. 69:1995;1420-1428.
15. Atabani S.F., Obeid O.E., Chargelegue D., Aaby P., Whittle H., Steward M.W. Identification of an immunodominant neutralising and protective epitope from measles virus fusion protein by using human sera from acute infection. J. Virol. 71:1997;7240-7245.
16. Merrifield R.B. Solid-phase peptide synthesis. Adv. Enzymol. Relat. Areas Mol. Biol. 32:1969;221-296.
17. Wiesmuller K.H., Spahn G., Handtmann D., Schneider F., Jung G., Muller C.P. Heterogeneity of linear B-cell epitopes of the measles virus fusion protein reacting with late convalescent sera. J. Gen. Virol. 73:1992;2211-2216.
18. Muller C.P., Bunder R., Mayser H., Ammon S., Weinmann M., Brons N.H., Schneider F., Jung G., Wiesmuller K.H. Intramolecular immunodominance and intermolecular selection of H2d-restricted peptides define the same immunodominant region of the measles virus fusion protein. Mol. Immunol. 32:1995;37-47.
19. Partidos C.D., Steward M.W. Prediction and identification of a T cell epitope in the fusion protein of measles virus immunodominant in mice and humans. J. Gen. Virol. 71:1990;2099-2105.
20. Demotz S., Lanzavecchia A., Eisel U., Niemann H., Widmann C., Corradin G. Delineation of several DR-restricted tetanus toxin T cell epitopes. J. Immunol. 142:1989;394-402.
21. Fournier P., Ammerlaan W., Ziegler D., Giminez C., Rabourdin-Combe C., Fleckenstein B.T., Wiesmuller K.H., Jung G., Schneider F., Muller C.P. Differential activation of T cells by antibody-modulated processing of the flanking sequences of class II-restricted peptides. Int. Immunol. 8:1996;1441-1451.
22. Ziegler D., Fournier P., Berbers G.A., Steuer H., Wiesmuller K.H., Fleckenstein B., Schneider F., Jung G., King C.C., Muller C.P. Protection against measles virus encephalitis by monoclonal antibodies binding to a cystine loop domain of the H protein mimicked by peptides which are not recognized by maternal antibodies. J. Gen. Virol. 77:1996;2479-2489.
23. Muller C.P., Beauverger P., Schneider F., Jung G., Brons N.H. Cholera toxin B stimulates systemic neutralising antibodies after intranasal co-immunisation with measles virus. J. Gen. Virol. 76:1995;1371-1380.
24. Huiss S., Damien B., Schneider F., Muller C.P. Characteristics of asymptomatic secondary immune responses to measles virus in late convalescent donors. Clin. Exp. Immunol. 109:1997;416-420.
25. Chargelegue D., Obeid O.E., Hsu S.C., Shaw M.D., Denbury A.N., Taylor G., Steward M.W. A peptide mimic of a protective epitope of respiratory syncytial virus selected from a combinatorial library induces virus-neutralising antibodies and reduces viral load in vivo. J. Virol. 72:1998;2040-2046.
26. Van der Werf S., Briand J.P., Plaue S., Burckard J., Girard M., Van Regenmortel M.H. Ability of linear and cyclic peptides of neutralisation antigenic site 1 of poliovirus type 1 to induce virus cross-reactive and neutralising antibodies. Res. Virol. 145:1994;349-359.
27. Gilleland L.B., Gilleland H.E. Jr. Synthetic peptides representing two protective, linear B-cell epitopes of outer membrane protein F of Pseudomonas aeruginosa elicit whole-cell-reactive antibodies that are functionally pseudomonad specific. Infect. Immun. 63:1995;2347-2351.
28. Simeckova-Rosenberg J., Yun Z., Wyde P.R., Atassi M.Z. Protection of mice against lethal viral infection by synthetic peptides corresponding to B- and T-cell recognition sites of influenza A hemagglutinin. Vaccine. 13:1995;927-932.
29. Enomoto A., Shon D.H., Aoki Y., Yamauchi K., Kaminogawa S. Antibodies raised against peptide fragments of bovine alpha s1-casein cross-react with the intact protein only when the peptides contain both B and T cell determinants. Mol. Immunol. 27:1990;581-586.
30. Geysen H.M., Barteling S.J., Meloen R.H. Small peptides induce antibodies with a sequence and structural requirement for binding antigen comparable to antibodies raised against the native protein. Proc. Natl. Acad. Sci. USA. 82:1985;178-182.
31. Snijders A., Benaissa-Trouw B.J., Snippe H., Kraaijeveld C.A. Immunogenicity and vaccine efficacy of synthetic peptides containing Semliki Forest virus B and T cell epitopes. J. Gen. Virol. 73:1992;2267-2272.
32. Brons N.H., Blaich A., Wiesmuller K.H., Schneider F., Jung G., Muller C.P. Hierarchic T-cell help to non-linked B-cell epitopes. Scand. J. Immunol. 44:1996;478-484.
33. Dintzis H.M., Dintzis R.Z., Vogelstein B. Molecular determinants of immunogenicity: the immunon model of immune response. Proc. Natl. Acad. Sci. USA. 73:1976;3671-3675.
34. Bachmann M.F., Hengartner H., Zinkernagel R.M. T helper cell-independent neutralising B cell response against vesicular stomatitis virus: role of antigen patterns in B cell induction? Eur. J. Immunol. 25:1995;3445-3451.
35. Gras-Masse H., Jolivet M., Drobecq H., Aubert J.P., Beachey E.H., Audibert F., Chedid L., Tartar A. Influence of helical organization on immunogenicity and antigenicity of synthetic peptides. Mol. Immunol. 25:1988;673-678.
36. Rehe G.T., Katona I.M., Brunswick M., Wahl L.M., June C.H., Mond J.J. Activation of human B lymphocytes by nanogram concentrations of anti-IgM-dextran conjugates. Eur. J. Immunol. 20:1990;1837-1842.
37. Wortis H.H., Teutsch M., Higer M., Zheng J., Parker D.C. B-cell activation by crosslinking of surface IgM or ligation of CD40 involves alternative signal pathways and results in different B-cell phenotypes. Proc. Natl. Acad. Sci. USA. 92:1995;3348-3352.
38. Ward B.J., Griffin D.E. Changes in cytokine production after measles virus vaccination: predominant production of IL-4 suggests induction of a Th2 response. Clin. Immunol. Immunopathol. 67:1993;171-177.
39. Servet-Delprat C., Bridon J.M., Djossou O., Yahia S.A., Banchereau J., Briere F. Delayed IgG2 humoral response in infants is not due to intrinsic T or B cell defects. Int. Immunol. 8:1996;1495-1502.
40. Adkins B., Du R.Q. Newborn mice develop balanced Th1/Th2 primary effector responses in vivo but are biased to Th2 secondary responses. J. Immunol. 160:1998;4217-4224.
41. Barrios C., Brawand P., Berney M., Brandt C., Lambert P.H., Siegrist C.A. Neonatal and early life immune responses to various forms of vaccine antigens qualitatively differ from adult responses: predominance of a Th2-biased pattern which persists after adult boosting. Eur. J. Immunol. 26:1996;1489-1496.
42. De Vries P., van Binnendijk R.S., van der Marel P., van Wezel A.L., Voorma H.O., Sundquist B., Uytdehaag F.G., Osterhaus A.D. Measles virus fusion protein presented in an immune-stimulating complex (iscom) induceshaemolysis-inhibiting and fusion-inhibiting antibodies, virus-specific T cells and protection in mice. J. Gen. Virol. 69:1988;549-559.
43. Marqusee S., Baldwin R.L. Helix stabilization by Glu-Lys+ salt bridges in short peptides of de novo design. Proc. Natl. Acad. Sci. USA. 84:1987;8898-8902.
44. Huyghues-Despointes B.M., Scholtz J.M., Baldwin R.L. Helical peptides with three pairs of Asp-Arg and Glu-Arg residues in different orientations and spacings. Protein Sci. 2:1993;80-85.
45. Shoemaker K.R., Kim P.S., Brems D.N., Marqusee S., York E.J., Chaiken I.M., Stewart J.M., Baldwin R.L. Nature of the charged-group effect on the stability of the C-peptide helix. Proc. Natl. Acad. Sci. USA. 82:1985;2349-2353.
46. Fraser R.D., Harrap B.S., Macrae T.P., Stewart F.H., Suzuki E. Effect of glycyl residues on the stability of the alpha-helix. Biopolymers. 5:1967;251-257.
47. Hawkins R.E., Russell S.J., Baier M., Winter G. The contribution of contact and non-contact residues of antibody in the affinity of binding to antigen. The interaction of mutant D1.3 antibodies with lysozyme. J. Mol. Biol. 234:1993;958-964.
48. Abaza M.S., Atassi M.Z. Effects of amino acid substitutions outside an antigenic site on protein binding to monoclonal antibodies of predetermined specificity obtained by peptide immunisation: demonstration with region 113-120 (antigenic site 4) of myoglobin. J. Protein Chem. 11:1992;677-686.